TENAX THERAPEUTICS INC (TENX)

US88032L6056 - Common Stock

4.24  +0.37 (+9.56%)

After market: 4.02 -0.22 (-5.19%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

TENAX THERAPEUTICS INC

NASDAQ:TENX (3/28/2024, 8:00:01 PM)

After market: 4.02 -0.22 (-5.19%)

4.24

+0.37 (+9.56%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap7.50M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

TENX Daily chart

Company Profile

Tenax Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Chapel Hill, North Carolina and currently employs 7 full-time employees. Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The firm is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The firm's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The firm is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The company has the rights to develop and commercialize IV (TNX-101), subcutaneous (TNX-102), and oral (TNX-103) formulations of levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The firm has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

Company Info

TENAX THERAPEUTICS INC

101 Glen Lennox Drive, Suite 300

Chapel Hill NORTH CAROLINA 27560

P: 19198552100

CEO: Anthony DiTonno

Employees: 7

Website: http://www.tenaxthera.com/

TENX News

News Image6 hours ago - InvestorPlaceTENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023

TENX stock results show that Tenax Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

News Image6 hours ago - BusinessInsiderTENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tenax Therapeutics (NASDAQ:TENX) just reported results for the fourth quarter o...

News Image20 hours ago - Tenax TherapeuticsTenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with...

News Image17 days ago - Tenax TherapeuticsTenax Therapeutics to Present at the 36th Annual Roth Conference

CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company...

News Imagea month ago - Tenax TherapeuticsTenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Dr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data highlighting the use of levosimendan for the treatment...

News Imagea month ago - Tenax TherapeuticsTenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

Amendment to existing exclusive license agreement with Orion Corporation expands Tenax’s territory rights from North America, to the entire worldExpanded...

TENX Twits

Here you can normally see the latest stock twits on TENX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example